Biologics vs small molecule drugs – what’s the difference?
19 November 2018
Biologics-based drugs have been increasing their market share over the last decade and the number of companies working with biologics keeps on growing. Last year, 17 new biologics-based drugs were approved by FDA, being the highest yearly approved number of biologics so far. The advances in biotechnology and analytical techniques have facilitated the development in the field, and will most likely continue doing so in the future.Read more
The ADME-Tox e-book series completed
8 October 2018
Our ADME-Tox e-book series, launched in April 2017, was just completed by the release of the fifth book “Permeability and transporters”. The e-book series was initiated to provide an easy-to-read source of information for those willing to learn more about ADME-Tox. The e-books have been written by our study directors, elucidating the science behind their areas of expertise for the readers.Read more
CYP induction assays – which way to go?
5 September 2018
In drug discovery and development, there are often several options available for addressing research questions, which may vary considerably in laboriousness, costs and the level of data they produce. Therefore, it is important to choose the right study set up at the right time to obtain correct and relevant answers for the project. As an example of different study approaches, let’s have a look at alternatives for studying CYP enzyme induction in vitro.Read more
Microsampling in in vivo PK studies
5 July 2018
Microsampling technology in drug discovery and development has been gaining a serious foothold within the industry over the last decade. We at Admescope have been providing microsampling as a part of our in vivo PK services for well over a year now and this feels like a good time to let Dr Janne Mannila, our Head of In vivo PK studies share his experiences with microsampling over an interview.Read more
In vitro toxicology screening in drug development
20 March 2018
Prior to IND approval drug candidates must go through a comprehensive battery of in vitro and in vivo toxicology testing to maximise safety in clinical trials. For ethical reasons and the costly nature of the in vivo animal tests the pharmaceutical industry relies more and more on in vitro methods for toxicity testing especially in drug discovery phase. To elucidate this topic further, we interviewed an expert on the subject, Dr Sanna-Mari Aatsinki.Read more